• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PD-L1 表达是乳腺癌术后患者基于 CIK 细胞的免疫治疗的预测性生物标志物。

PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.

机构信息

Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China.

Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China.

出版信息

J Immunother Cancer. 2019 Aug 27;7(1):228. doi: 10.1186/s40425-019-0696-8.

DOI:10.1186/s40425-019-0696-8
PMID:31455411
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6712838/
Abstract

BACKGROUND

A sequential combination of radiochemotherapy/endocrinotherapy and cytokine-induced killer cell (CIK) infusion has been shown to be an effective therapy for post-mastectomy breast cancer based on statistical analysis of the patient population. However, whether an individual could obtain an improved prognosis from CIK cell-based treatment remains unknown. In the present study, we focused on immune microenvironment regulation and specifically investigated the relationship between PD-L1 expression and survival benefit from CIK immunotherapy in breast cancer.

METHODS

A total of 310 postoperative breast cancer patients who received comprehensive treatment were enrolled in this retrospective study, including 160 patients in the control group (received chemotherapy/radiotherapy/endocrinotherapy) and 150 patients in the CIK cell treatment group (received chemotherapy/radiotherapy/ endocrinotherapy and subsequent CIK infusion).

RESULTS

We found that overall survival (OS) and recurrence-free survival (RFS) were significantly better in the CIK group than that in the control group. PD-L1 expression in tumor tissue sections was showed to be an independent prognostic factor for patients in the CIK treatment group using multivariate survival analysis. Further survival analysis in the CIK group showed that patients with PD-L1 tumor expression exhibited longer OS and RFS. In addition, among all patients who were enrolled in this study, only the patients with PD-L1 expression experienced survival benefits from CIK treatment.

CONCLUSIONS

Our study showed the relationship between PD-L1 expression and CIK therapy and revealed that PD-L1 expression in the tumor is as an indicator of adjuvant CIK therapy for postoperative breast cancer.

摘要

背景

基于对患者人群的统计学分析，放射化学疗法/内分泌疗法与细胞因子诱导的杀伤细胞（CIK）输注的序贯联合已被证明是一种治疗乳腺癌根治术后的有效疗法。然而，CIK 细胞治疗是否能使个体获得更好的预后尚不清楚。在本研究中，我们专注于免疫微环境的调节，并特别研究了 PD-L1 表达与乳腺癌患者接受 CIK 免疫治疗的生存获益之间的关系。

方法

本回顾性研究共纳入 310 例接受综合治疗的乳腺癌术后患者，其中对照组（接受化疗/放疗/内分泌治疗）160 例，CIK 细胞治疗组（接受化疗/放疗/内分泌治疗和后续 CIK 输注）150 例。

结果

我们发现 CIK 组的总生存期（OS）和无复发生存期（RFS）明显优于对照组。多变量生存分析显示，PD-L1 肿瘤组织切片的表达是 CIK 治疗组患者的独立预后因素。对 CIK 组的进一步生存分析显示，PD-L1 肿瘤表达的患者具有更长的 OS 和 RFS。此外，在所有入组患者中，只有 PD-L1 表达的患者从 CIK 治疗中获益。

结论

本研究显示了 PD-L1 表达与 CIK 治疗之间的关系，并表明肿瘤中的 PD-L1 表达是乳腺癌术后辅助 CIK 治疗的一个指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/b47b10e48505/40425_2019_696_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/b4548bbd3812/40425_2019_696_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/d4da1b84ff73/40425_2019_696_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/627ac4fe8f47/40425_2019_696_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/75d3b12344e2/40425_2019_696_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/ed0873c8f2f1/40425_2019_696_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/ca51f3cb3aff/40425_2019_696_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/b47b10e48505/40425_2019_696_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/b4548bbd3812/40425_2019_696_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/d4da1b84ff73/40425_2019_696_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/627ac4fe8f47/40425_2019_696_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/75d3b12344e2/40425_2019_696_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/ed0873c8f2f1/40425_2019_696_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/ca51f3cb3aff/40425_2019_696_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9d7/6712838/b47b10e48505/40425_2019_696_Fig7_HTML.jpg

相似文献

1
PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.PD-L1 表达是乳腺癌术后患者基于 CIK 细胞的免疫治疗的预测性生物标志物。
J Immunother Cancer. 2019 Aug 27;7(1):228. doi: 10.1186/s40425-019-0696-8.
2
High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.肿瘤内 PD-1 阳性淋巴细胞数量高可预测细胞因子诱导的杀伤细胞治疗肝癌患者的生存获益。
Liver Int. 2018 Aug;38(8):1449-1458. doi: 10.1111/liv.13697. Epub 2018 Feb 13.
3
Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.辅助细胞因子诱导的杀伤细胞免疫疗法在乳腺癌根治术后三阴性乳腺癌患者中的临床活性。
Clin Cancer Res. 2014 Jun 1;20(11):3003-11. doi: 10.1158/1078-0432.CCR-14-0082. Epub 2014 Mar 25.
4
PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.程序性死亡配体1（PD-L1）表达作为肝细胞癌患者细胞因子诱导的杀伤细胞免疫治疗的预测生物标志物。
Oncoimmunology. 2016 May 31;5(7):e1176653. doi: 10.1080/2162402X.2016.1176653. eCollection 2016 Jul.
5
The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients.细胞因子诱导的杀伤细胞输注作为辅助治疗用于肝癌术后患者的疗效。
Ann Surg Oncol. 2013 Dec;20(13):4305-11. doi: 10.1245/s10434-013-3144-x. Epub 2013 Jul 27.
6
2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer.2003年至2013年，一项有价值的研究：自体肿瘤裂解物脉冲树突状细胞免疫疗法联合细胞因子诱导的杀伤细胞可提高IV期乳腺癌患者的生存率。
Immunol Lett. 2017 Mar;183:37-43. doi: 10.1016/j.imlet.2017.01.014. Epub 2017 Jan 29.
7
CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma.CIK 细胞细胞毒性是预测肝癌术后患者 CIK 细胞免疫治疗的生物标志物。
Cancer Immunol Immunother. 2020 May;69(5):825-834. doi: 10.1007/s00262-020-02486-y. Epub 2020 Feb 14.
8
Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment.树突状细胞-细胞因子诱导的杀伤细胞联合一线治疗对晚期结直肠癌患者的影响。
World J Surg Oncol. 2017 Nov 28;15(1):209. doi: 10.1186/s12957-017-1278-1.
9
Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences.选择适当的大剂量化疗联合树突状细胞和细胞因子诱导的杀伤细胞过继细胞疗法可改善转移性乳腺癌患者的无进展生存期和总生存期：对这种有争议的治疗偏好的重新论证。
Clin Transl Oncol. 2013 Oct;15(10):780-8. doi: 10.1007/s12094-013-1001-9. Epub 2013 Jan 29.
10
Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer.术前中性粒细胞与淋巴细胞比值对胃癌根治性切除联合CIK辅助免疫治疗及术后化疗后生存率的预测价值
J Cancer Res Clin Oncol. 2017 May;143(5):861-871. doi: 10.1007/s00432-016-2330-1. Epub 2017 Jan 20.

引用本文的文献

1
Current status of cytokine-induced killer cells and combination regimens in breast cancer.细胞因子诱导的杀伤细胞及联合方案在乳腺癌中的研究现状
Front Immunol. 2025 Feb 6;16:1476644. doi: 10.3389/fimmu.2025.1476644. eCollection 2025.
2
ZG16 enhances the maturation of dendritic cells via induction of CD40 and contributes to the antitumor immunity in pancreatic cancer.ZG16 通过诱导 CD40 增强树突状细胞的成熟，并有助于胰腺癌的抗肿瘤免疫。
Oncogene. 2024 Oct;43(43):3184-3196. doi: 10.1038/s41388-024-03154-6. Epub 2024 Sep 11.
3
Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer.

本文引用的文献

1
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌。
N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.
2
Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinants.非洲的乳腺癌：患病率、治疗选择、草药和社会经济决定因素。
Breast Cancer Res Treat. 2017 Nov;166(2):351-365. doi: 10.1007/s10549-017-4408-0. Epub 2017 Aug 4.
3
Breast cancer complexity: implications of intratumoral heterogeneity in clinical management.
免疫检查点抑制剂在胆囊癌患者中的疗效和预测因素。
Cancer Sci. 2024 Jun;115(6):1979-1988. doi: 10.1111/cas.16142. Epub 2024 Mar 15.
4
Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma.评估 NY-ESO-1 特异性 TCR T 细胞在 HLA-A∗02:01 晚期软组织肉瘤患者中的安全性和疗效的 1 期临床试验。
Cell Rep Med. 2023 Aug 15;4(8):101133. doi: 10.1016/j.xcrm.2023.101133.
5
PTPRD/PTPRT mutation correlates to treatment outcomes of immunotherapy and immune landscape in pan-cancers.PTPRD/PTPRT突变与泛癌中免疫治疗的疗效及免疫格局相关。
Chin J Cancer Res. 2023 Jun 30;35(3):316-330. doi: 10.21147/j.issn.1000-9604.2023.03.09.
6
Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape.基于免疫基因组景观的 HER2 阳性乳腺癌新型免疫亚型鉴定。
Med Oncol. 2022 May 15;39(5):92. doi: 10.1007/s12032-022-01690-3.
7
Association of mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors.免疫检查点抑制剂在泛癌中的突变与更好临床结局的关联。
Am J Cancer Res. 2022 Apr 15;12(4):1766-1783. eCollection 2022.
8
The role of long non-coding RNA FGD5-AS1 in cancer.长链非编码 RNA FGD5-AS1 在癌症中的作用。
Bioengineered. 2022 Apr;13(4):11026-11041. doi: 10.1080/21655979.2022.2067292.
9
Tumor collection/processing under physioxia uncovers highly relevant signaling networks and drug sensitivity.在生理性氧分压条件下进行肿瘤采集/处理可揭示高度相关的信号网络和药物敏感性。
Sci Adv. 2022 Jan 14;8(2):eabh3375. doi: 10.1126/sciadv.abh3375. Epub 2022 Jan 12.
10
The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer.三阴性乳腺癌的肿瘤微环境特征
Cancer Manag Res. 2022 Jan 3;14:1-17. doi: 10.2147/CMAR.S316700. eCollection 2022.
乳腺癌的复杂性：肿瘤内异质性在临床管理中的影响
Cancer Metastasis Rev. 2017 Sep;36(3):547-555. doi: 10.1007/s10555-017-9684-y.
4
Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy.细胞因子诱导的杀伤细胞作为癌症免疫治疗的药理学工具
Front Immunol. 2017 Jul 6;8:774. doi: 10.3389/fimmu.2017.00774. eCollection 2017.
5
Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma.肿瘤程序性死亡配体1（PD-L1）表达与阴茎鳞状细胞癌中肿瘤浸润淋巴细胞（TILs）增加及预后不良相关。
Oncoimmunology. 2016 Dec 22;6(2):e1269047. doi: 10.1080/2162402X.2016.1269047. eCollection 2017.
6
Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.肿瘤浸润淋巴细胞的组成、组织方式及PD-1/PD-L1表达在乳腺癌中存在关联。
Oncoimmunology. 2016 Dec 14;6(1):e1257452. doi: 10.1080/2162402X.2016.1257452. eCollection 2017.
7
Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.细胞因子诱导的杀伤细胞能杀死化疗幸存的黑素瘤癌症干细胞。
Clin Cancer Res. 2017 May 1;23(9):2277-2288. doi: 10.1158/1078-0432.CCR-16-1524. Epub 2016 Nov 4.
8
Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma.程序性死亡配体1作为人类肝细胞癌中预先存在的适应性免疫反应的指标。
Oncoimmunology. 2016 May 13;5(7):e1181252. doi: 10.1080/2162402X.2016.1181252. eCollection 2016 Jul.
9
PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.程序性死亡配体1（PD-L1）表达作为肝细胞癌患者细胞因子诱导的杀伤细胞免疫治疗的预测生物标志物。
Oncoimmunology. 2016 May 31;5(7):e1176653. doi: 10.1080/2162402X.2016.1176653. eCollection 2016 Jul.
10
PD-L1 in non-small-cell lung cancer: the third target for immunotherapy.非小细胞肺癌中的程序性死亡受体配体1（PD-L1）：免疫治疗的第三个靶点
Lancet. 2016 Apr 30;387(10030):1795-6. doi: 10.1016/S0140-6736(16)00700-5. Epub 2016 Mar 10.